1. Baseline characteristics of included studies.
| Study name | Trial period (year to year) | Setting/country | Description of participants |
Intervention(s) and comparator(s) |
Duration of follow‐up | Age (mean ± SD) |
IPSS (mean ± SD) |
Prostate volume (mean ± SD) |
| Gratzke 2017 | February 2012 to October 2013 | 10 centres/Europe | Men aged ≥ 50 years with IPSS > 12, Qmax ≤ 15 mL/second for 125 mL voided volume, postvoid residual volume < 350 mL, prostate volume ≤ 60 mL on ultrasound, sexually active within 6 months before the index procedure, Sexual Health Inventory for Men score > 6, positive response to MSHQ‐EjD (excluding the response "Could not ejaculate"), Incontinence Severity Index score ≤ 4 | PUL | 24 months | 63 ± 6.8 years | 22 ± 5.7 | 38 ± 12 mL |
| TURP | 65 ± 6.4 years | 23 ± 5.9 | 41 ± 13 mL | |||||
| Roehrborn 2013 | February to December 2011 | 19 centres/US, Canada, and Australia | Men ≥ 50 years old, provided informed consent, had no prior surgical treatment for BPH, and were required to undergo washouts of 2 weeks for alpha‐blocker, 3 months for 5a‐reductase inhibitor, and 3 days for anticoagulants. Admission to the study required AUASI ≥ 13, Qmax ≤ 12 mL/second with a 125 mL voided volume and a 30–80 mL prostate volume | PUL | 3 months | 67 ± 8.6 year | 22.2 ± 5.48 | 44.5 ± 12.4 mL |
| Sham | 65 ± 8.0 years | 24.4 ± 5.75 | 40.9 ± 10.8 mL |
AUASI: American Urological Association Symptom Index; BPH: benign prostatic hyperplasia; IPSS: International Prostate Symptom Score; MSHQ‐EjD: Male Sexual Health Questionnaire for Ejaculatory Dysfunction; PUL: prostatic urethral lift; Qmax: maximum flow rate; TURP: transurethral resection of prostate.